Which path will you take?
By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a target-market approach to increase revenue.
Pharma 2020: Marketing the future - Which path will you take? the third in the Pharma 2020 series, outlines a confluence of dynamics that lead to a new marketing and sales system with a smaller, more agile and smarter sales force. The pharma industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies will need to demonstrate that their brand adds value to patients and they will have to offer a package of products and health services that the market not only wants and needs but is willing to pay a premium for. The paper highlights some very strong facts related to the need for Pharma to change its marketing and sales functions in order to sustain future growth and performance.
This report outlines in some detail what those changes in the business environment will be and provides pharma companies with indicators of organisational and operational structure that could influence their success and readiness to compete.
This report highlights the fundamental dynamics the industry faces that are reshaping the pharmaceutical marketplace:
In order to be successful, companies will need to stop the aggressive marketing focusing only on the product of the current model and:
Global Pharmaceutical and Life Sciences Advisory Leader, PwC United States
Tel: +1 (267) 330 3045
Global Pharmaceutical and Life Sciences Assurance Leader, PwC Switzerland
Tel: +41 79 5429018
Global Pharmaceutical and Life Sciences Tax Leader, PwC United Kingdom
Tel: +44 (0)771 266 64 41